Imprimis Pharmaceuticals and Focus Script have collaboratively launched the Correct Compound program, which provides a customizable formulary through the CDF-Logic program as a specialized compound pharmacy care solution. Read More »
Shionogi & Co. Ltd., its subsidiary Shionogi Inc. and Purdue Pharma will launch Symproic, also known as naldemedine, to treat adult patients with chronic non-cancer pain who have opioid-induced constipation. Read More »
Integrated Delivery Networks are continuing to form with the continued growth and mergers of health systems. Read More »
Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »
Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of Acanthamoeba Keratitis. Read More »
Ionis Pharmaceuticals posted earnings of $28 million from AstraZeneca due to the finalization of AstraZeneca’s studies supporting IND and the licensing of IONIS-KRAS-2.5Rx, also known as AZD4785. Read More »
Eli Lilly and Co., along with Incyte Corp., have announced that baricitinib received a positive opinion as well as a recommendation for approval from the European Medicines Agency Committee for Medicinal Products for Human Use. Read More »
CVS Health recently held its annual Analyst Day, a meeting in which the discussions of strategies for long-term growth will be driven and shareholder value were held. Read More »
The results of a new study conducted by AARP show that pharmaceutical prices for brand name products has increased drastically. Read More »
Endo International subsidiary Par Pharmaceutical has begun the shipping process for ezetimibe 10 mg tablets, which is the generic form of ZETIA, developed by Merck. Read More »
EMD Serono, subsidiary of Merck KGaA, has appointed Brian Barry as its chief compliance officer with oversight of the development and execution of EMD Serono’s comprehensive compliance program. Read More »
Protagen AG has launched NavigAID SSc, its disease stratification assay that was developed to assist pharmaceutical and biotechnology companies with their efforts to develop drugs to treat Systemic Sclerosis. Read More »
Bayer's supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator has been accepted by the U.S. Food and Drug Administration. Read More »
Castle Creek Pharmaceuticals' exclusive license agreement for the rights to Arlevert in the United States has been finalized. Read More »
AcelRx Pharmaceuticals has submitted a New Drug Application for ARX-04 (sufentanil sublingual tablet, 30 mcg) to the U.S. Food and Drug Administration. Read More »
aTyr Pharma has released results of its exploratory clinical trials designed to evaluate the safety and potential activity of Resolaris in treating LGMD2B and FSHD. Read More »
Cognition Therapeutics has initiated testing of CT1812 in clinical trials in the United States. Read More »
CVS Health has launched Transform Diabetes Care, its new program set up to assist pharmacy benefits management clients in the improvement of member health outcomes, to decrease costs with aggressive trend management, and to cut medical costs by refining medication adherence. Read More »
Merck recently released KEYTRUDA data demonstrating an overall response rate of 41 percent in patients with relapsed or refractory primary mediastinal large B-cell lymphoma. Read More »
Merck continued its release of KEYTRUDA results by reporting that its Phase 3 KEYNOTE-024 clinical trial demonstrated positive health-related quality of life. Read More »
Alerts Sign-up
